ImmunoGen Signs 2nd Licensing Deal with Amgen
ImmunoGen has licensed its anti-cancer technology to Amgen for an upfront payment of $1 million.
442
Osteologix to Continue Development of Osteoporosis Drug
Osteologix is positioning NB S101 as an alternative to traditional osteoporosis treatments.
FDA Approves Centocor’s Psoriasis Treatment
After a long delay, Centocor Ortho Biotech’s psoriasis drug Stelara has been approved by the U.S. Food and Drug Administration.
Nasdaq Buoyed by Biotech
The Nasdaq rose 5 points on Monday, due in part to recent happenings in the biopharmaceutical sector.
The Key to Stopping Colon Cancer?
Scientists in Switzerland may have found a way to inhibit the growth of colon cancer in humans, says a new study published in EMBO Molecular Medicine.